Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...

Elranatamab is recommended with managed access as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Tools to help you put the guidance into practice.

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

Elranatamab (Elrexfio, Pfizer) is indicated 'as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, ...

NICE is unable, at this time, to make a recommendation about the use in the NHS of toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...